BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 26527523)

  • 21. Evaluation of androgen receptor and GATA binding protein 3 as immunohistochemical markers in the diagnosis of metastatic breast carcinoma to the lung.
    Hattori Y; Yoshida A; Yoshida M; Takahashi M; Tsuta K
    Pathol Int; 2015 Jun; 65(6):286-92. PubMed ID: 25727644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of GATA3 immunostaining in tumor diagnosis: a review.
    Ordóñez NG
    Adv Anat Pathol; 2013 Sep; 20(5):352-60. PubMed ID: 23939152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
    Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
    Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunohistochemical evaluation of GATA-3 expression in ER-negative breast carcinomas.
    Liu H; Shi J; Prichard JW; Gong Y; Lin F
    Am J Clin Pathol; 2014 May; 141(5):648-55. PubMed ID: 24713735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
    Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
    J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GATA3 expression in triple-negative breast cancers.
    Byrne DJ; Deb S; Takano EA; Fox SB
    Histopathology; 2017 Jul; 71(1):63-71. PubMed ID: 28211079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
    Lew M; Pang JC; Jing X; Fields KL; Roh MH
    Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression.
    Hafez NH; Shaaban HM
    Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
    Miettinen M; McCue PA; Sarlomo-Rikala M; Rys J; Czapiewski P; Wazny K; Langfort R; Waloszczyk P; Biernat W; Lasota J; Wang Z
    Am J Surg Pathol; 2014 Jan; 38(1):13-22. PubMed ID: 24145643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
    Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
    Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GATA-3 expression in male and female breast cancers: comparison of clinicopathologic parameters and prognostic relevance.
    Gonzalez RS; Wang J; Kraus T; Sullivan H; Adams AL; Cohen C
    Hum Pathol; 2013 Jun; 44(6):1065-70. PubMed ID: 23266442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRPS1 is a Highly Sensitive Marker for Breast Cancer: A Tissue Microarray Study Evaluating More Than 19,000 Tumors From 152 Different Tumor Entities.
    Lennartz M; Löhr N; Höflmayer D; Dwertmann Rico S; von Bargen C; Kind S; Reiswich V; Viehweger F; Lutz F; Bertram V; Fraune C; Gorbokon N; Weidemann S; Blessin NC; Hube-Magg C; Menz A; Schlichter R; Krech T; Hinsch A; Burandt E; Sauter G; Simon R; Kluth M; Marx AH; Lebok P; Dum D; Minner S; Jacobsen F; Clauditz TS; Bernreuther C; Steurer S
    Am J Surg Pathol; 2024 Jun; 48(6):637-651. PubMed ID: 38647255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression analysis of invasive breast carcinoma yields differential patterns in luminal subtypes of breast cancer.
    Abdelhafiz AS; Fouda MA; Elzefzafy NA; Taha II; Mohemmed OM; Alieldin NH; Toony I; Abdel Wahab AA; Farahat IG
    Ann Diagn Pathol; 2021 Dec; 55():151814. PubMed ID: 34517157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of GATA3 immunohistochemistry in differentiating urothelial carcinoma from prostate adenocarcinoma and squamous cell carcinomas of the uterine cervix, anus, and lung.
    Chang A; Amin A; Gabrielson E; Illei P; Roden RB; Sharma R; Epstein JI
    Am J Surg Pathol; 2012 Oct; 36(10):1472-6. PubMed ID: 22982890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A combination of p40, GATA-3 and uroplakin II shows utility in the diagnosis and prognosis of muscle-invasive urothelial carcinoma.
    Leivo MZ; Elson PJ; Tacha DE; Delahunt B; Hansel DE
    Pathology; 2016 Oct; 48(6):543-9. PubMed ID: 27594510
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
    Piao ZH; Zhou XC; Chen JY
    Virchows Arch; 2021 Aug; 479(2):257-263. PubMed ID: 33570661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients.
    Govindan S; Siraganahalli Eswaraiah M; Basavaraj C; Adinarayan M; Sankaran S; Bakre M
    BMC Cancer; 2020 Aug; 20(1):745. PubMed ID: 32778063
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GATA3 expression in metastatic urothelial carcinoma in fine needle aspiration cell blocks: a review of 25 cases.
    Siddiqui MT; Seydafkan S; Cohen C
    Diagn Cytopathol; 2014 Sep; 42(9):809-15. PubMed ID: 24578300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uroplakin II (UPII), GATA3, and p40 are Highly Sensitive Markers for the Differential Diagnosis of Invasive Urothelial Carcinoma.
    Hoang LL; Tacha D; Bremer RE; Haas TS; Cheng L
    Appl Immunohistochem Mol Morphol; 2015; 23(10):711-6. PubMed ID: 25611245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic relevance of FOXA1 and Nestin expression in breast cancer metastases: a retrospective study of 164 cases during a 10-year period (2004-2014).
    De Lara S; Nyqvist J; Werner Rönnerman E; Helou K; Kenne Sarenmalm E; Einbeigi Z; Karlsson P; Parris TZ; Kovács A
    BMC Cancer; 2019 Feb; 19(1):187. PubMed ID: 30819139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.